Document:

<PAGE>

                                                                    Exhibit 10.1

                        SETTLEMENT AGREEMENT AND RELEASE

               THIS SETTLEMENT AGREEMENT AND RELEASE (this "Settlement
Agreement") is made this August 1, 2002, by and among VIROPHARMA INCORPORATED, a
Delaware corporation ("ViroPharma"), VCO INCORPORATED, a Delaware corporation
and wholly-owned subsidiary of ViroPharma ("VCO"), and AVENTIS PHARMACEUTICALS,
INC., a Delaware corporation ("Aventis"). For convenience, each of ViroPharma,
VCO and Aventis may be referred to in this Settlement Agreement as a "Party" and
collectively as "Parties."

                                   Background

               ViroPharma and Aventis are parties to that certain Copromotion
and Codevelopment Agreement, effective as of September 9, 2001, as amended (the
"Copromotion Agreement"). ViroPharma and Aventis are also parties to that
certain Stock Purchase Agreement, dated as of September 9, 2001 (the "Stock
Purchase Agreement"). Pursuant to that certain Sublicense and Subcontract
Agreement between ViroPharma and VCO, dated December 31, 2001 (the "VCO
Subcontract Agreement"), ViroPharma subcontracted and sublicensed to VCO certain
of ViroPharma's obligations and rights under the Copromotion Agreement.

               As a result of developments that have occurred since the
Effective Date of the Copromotion Agreement, the Parties have determined in good
faith to terminate such Copromotion Agreement and the Stock Purchase Agreement
without the payment of a termination fee.

               In consideration of the mutual covenants and releases contained
in this Settlement Agreement and for other good and valuable consideration, the
receipt and sufficiency of which are hereby acknowledged, the parties, intending
to be legally bound, hereby agree as follows:

               1. Certain Capitalized Terms. Capitalized terms used in this
Settlement Agreement shall have the respective meanings ascribed to such terms
in the Copromotion Agreement and in this Settlement Agreement.

               2. Settlement and Termination of the Copromotion Agreement and
Stock Purchase Agreement. ViroPharma and Aventis hereby settle and resolve all
claims that they may have against each other under the Copromotion Agreement and
terminate each of the Copromotion Agreement and Stock Purchase Agreement in all
respects (including, without limitation, Sections 13.10 and 13.11 of the
Copromotion Agreement) effective as of the date of this Settlement Agreement,
and no further amounts shall be due or payable by Aventis or ViroPharma to the
other under or in connection with either or both of the Copromotion Agreement or
the Stock Purchase Agreement and neither Aventis nor ViroPharma shall have any
continuing or further obligation with respect to any representation, warranty,
obligation, covenant or agreement under either or both of the Copromotion
Agreement or the Stock Purchase Agreement except in each case as otherwise
provided in (a) Section 1 of this Settlement Agreement with respect to certain
capitalized terms, (b) Section 5 of this Settlement Agreement, and (c) Section
10(a) of this Settlement Agreement.

<PAGE>

               3. Mutual Releases.

                    (a) By ViroPharma.  Subject to Section 3(c) of this
Settlement Agreement, ViroPharma, for itself and anyone claiming by, through or
under ViroPharma, including, without limitation, VCO, hereby knowingly and
voluntarily releases and forever discharges Aventis and its Affiliates, and
their past and present shareholders, partners, directors, officers, employees,
agents and attorneys of any of the foregoing, and the predecessors, successors,
assigns, heirs and personal representatives of any of the foregoing, and all
insurers of any of the foregoing (collectively with Aventis, the "Aventis
Parties") of and from any and all claims, duties, obligations, liabilities,
debts, demands, expenses, costs, actions, and causes of action, whether at law
or in equity, known or unknown, accrued or unaccrued, matured or unmatured,
individually or derivatively, that ViroPharma or anyone claiming by, through or
under ViroPharma had, may have, or now have under, or that might subsequently
accrue or arise out of, or concern, either or both of the Copromotion Agreement
and the Stock Purchase Agreement.

                    (b) By Aventis.  Subject to Section 3(c) of this Settlement
Agreement, Aventis, for itself and anyone claiming by, through or under Aventis,
hereby knowingly and voluntarily releases and forever discharges ViroPharma and
its Affiliates, and their past and present shareholders, partners, directors,
officers, employees, agents and attorneys of any of the foregoing, and the
predecessors, successors, assigns, heirs and personal representatives of any of
the foregoing, and all insurers of any of the foregoing (collectively with
ViroPharma, the "ViroPharma Parties") of and from any and all claims, duties,
obligations, liabilities, debts, demands, expenses, costs, actions, and causes
of action, whether at law or in equity, known or unknown, accrued or unaccrued,
matured or unmatured, individually or derivatively, that Aventis or anyone
claiming by, through or under Aventis had, may have, or now have under, or that
might subsequently accrue or arise out of, or concern, either or both of the
Copromotion Agreement and the Stock Purchase Agreement.

                    (c) Exceptions. Nothing contained in this Settlement
Agreement shall settle, release, discharge or otherwise affect any of the
Parties' respective representations, warranties, obligations, agreements and
covenants under this Settlement Agreement.

               4. No Admission. The entry into this Settlement Agreement by
ViroPharma and VCO, on the one hand, and Aventis, on the other hand, does not
constitute an admission by any of them as to the merit or lack of merit of any
claims brought or that could have been brought against the other or any defenses
asserted or that could have been asserted with respect thereto, nor does it
constitute an admission by any of the Parties for any other purpose. Rather,
each of the Parties is entering into this Settlement Agreement without making
any admissions, and is doing so solely to avoid the expense that would be
involved in proceeding any further with their dispute regarding the Copromotion
Agreement.

                                      -2-

<PAGE>

               5. Payment for ViroPharma Commercialization and Development
Expenses; Details and Calls; Accelerated Refund; and Stock Purchase.

                    (a)  Payment for Commercialization and Development Expenses.
Notwithstanding anything to the contrary in this Settlement Agreement, Sections
8.5.1, 8.5.2, 8.5.3, 8.5.4, 8.6, 8.8, 8.9 and 8.10 of the Copromotion Agreement
shall survive the termination of the Copromotion Agreement until the date that
the Parties make final payment pursuant to Section 8.5.4 of the Copromotion
Agreement with respect to the period ending on the date of this Settlement
Agreement, and Section 8.11 shall survive until the third anniversary of this
Settlement Agreement.

                    (b)  Detail of Aventis Product. With respect to the
continued Detailing of Aventis Products after the date of this Settlement
Agreement the following shall apply:

                         (i)    Continued Detailing of Aventis Products.
Article 9 of the Copromotion Agreement shall survive the termination of the
Copromotion Agreement until August 31, 2002, and, for the sake of clarity,
ViroPharma shall continue to have the right and license to perform Details and
Calls with respect to the Aventis Products in accordance with the terms and
subject to the conditions set forth in Article 9 of the Copromotion Agreement
and to perform all other activities described therein (and VCO may continue to
act as ViroPharma's sublicensee and contractor under the VCO Subcontract
Agreement with respect thereto) until August 31, 2002.

                         (ii)   Payment for Details and Calls Through August 31,
2002. Notwithstanding anything to the contrary in this Settlement Agreement,
Section 9.4.3 and 9.6.3 of the Copromotion Agreement shall survive the
termination of the Copromotion Agreement until the date that the Parties make
final payment pursuant to Sections 9.4.3 of the Copromotion Agreement with
respect to the period ending on August 31, 2002.

                         (iii)  Manner of Payments. Aventis shall pay all
amounts to be paid to ViroPharma under this Section 5(b) in United States
Dollars by wire transfer in immediately available funds to the same bank account
to which Aventis made previous payments to ViroPharma under the Copromotion
Agreement.

                         (iv)   Late Payments. If any payment under this Section
5(b) is not made when due, interest shall accrue on the past due amount at a
rate per annum equal to the lower of (i) the highest interest rate permitted by
applicable law and (ii) the prime rate for the first date on which such payment
was delinquent, as quoted in the "Money Rates" Section of the Wall Street
Journal, in either case, calculated on an actual/360 basis.

                         (v)    Non-applicability of Section 9.5.2. For the sake
of clarity, ViroPharma and Aventis confirm that since the Parties agree
hereunder to terminate the Copromotion Agreement as a whole, Section 9.5.2 of
the Copromotion Agreement does not apply and that Aventis shall in any event not
be required to make a payment as described in Section 9.5.2 of the Copromotion
Agreement.

                                      -3-

<PAGE>

                    (c)  Accelerated Refund. Sections 8.1.1(a-b) of the
Copromotion Agreement are hereby implemented as if the dates written therein
were in each instance August 1, 2002 such that the aggregate amount of twenty
million U.S. dollars (U.S. $20,000,000) described in such Sections 8.1.1(a-b) is
hereby made due and payable as of the date of this Settlement Agreement.

                    (d)  Stock Purchase. Aventis shall purchase from ViroPharma
and ViroPharma shall issue to Aventis on the date of this Settlement Agreement a
total of three million (3,000,000) fully paid and non-assessable shares of
ViroPharma's common stock, par value $0.002 per share (collectively, the
"Shares") at a price equal to $1.53 per Share, for a total of four million, five
hundred ninety thousand U.S. dollars (U.S. $4,590,000), which amount shall be
due and payable on the date of this Settlement Agreement. The Shares have been
registered on a Form S-3, File No. 333-64482, which registration statement has
been declared effective by the Securities and Exchange Commission. The Shares,
when delivered, will be free of restrictive legends. ViroPharma shall deliver a
prospectus supplement pursuant to Rule 424(b)(2) under the Securities Act of
1933, as amended, regarding the sale of the Shares prior to issuance of the
Shares to Aventis. The Shares shall be issued, and a stock certificate
evidencing the Shares delivered, to Aventis promptly following the filing of
such supplement by ViroPharma. Within forty-five (45) days after the date of
this Settlement Agreement, ViroPharma shall also file a new registration
statement on Form S-3 (or post-effective amendment to the Form S-3 referenced
above, if eligible) to enable Aventis to sell the Shares pursuant to a resale
prospectus to be included in such registration statement, pursuant to the terms
and conditions of the Registration Rights Agreement executed by ViroPharma and
Aventis simultaneously with this Settlement Agreement.

             6. Confidentiality; Return/Destruction of Confidential Information.

                    (a)  General Prohibition on Disclosure and Use. Except to
the extent expressly authorized by this Settlement Agreement, or otherwise
agreed in writing by the Parties, for a time period of ten (10) years as of the
date of this Settlement Agreement, each Party shall, and shall cause any
Affiliate to, maintain in confidence with at least the same degree of care it
uses for such Party's own confidential information, but no less than reasonable
care, and shall not use any Confidential Information (as defined in Section 6(d)
of this Settlement Agreement) of the other Party for any purpose other than
archival purposes. Each Party will promptly notify the other Party upon
discovery of any unauthorized use or disclosure of such other Party's
Confidential Information. Any breach of this obligation of confidentiality or
non-use by any Affiliate, director, officer, employee, agent, consultant, or
sublicensee of a Party or any of such Party's Affiliates shall be deemed a
breach by that Party.

                    (b)  Permitted Disclosure and Use. Notwithstanding Section
6(a) of this Settlement Agreement, a Party may disclose Confidential Information
belonging to the other Party only to the extent such disclosure is reasonably
necessary to:

                         (i)   enforce the provisions of this Settlement
Agreement; or

                         (ii)  comply with any requirements of law or of any
court, or arbitration panel, or any federal, state, local or foreign
governmental body, regulator, agency, commission, bureau, or authority; or

                                      -4-

<PAGE>

                         (iii)  comply with the requirements of the SaSy
Agreement.

If a Party deems it necessary to disclose Confidential Information of the other
Party pursuant to this Section 6(b)(ii), then such Party shall give reasonable
advance notice of such disclosure to the other Party to permit such other Party
sufficient opportunity to object to such disclosure or to take measures to
ensure confidential treatment of such information.

                    (c)  Return/Destruction of Confidential Information. Without
limitation to the other provisions of this Section 6, each Party shall either
(i) return to the other Party all Confidential Information of such other Party
or (ii) destroy all Confidential Information of the other Party and all copies
of any documents, items and materials which includes or contains any such
Confidential Information or summaries, compilations or analyses thereof and
provide the other Party with a written certified statement that all such
documents, items and materials have been so destroyed and that such Party and
its Affiliates are no longer in possession or control of any such documents,
items and materials, in each case, within thirty (30) days after the date of
this Settlement Agreement. Notwithstanding the foregoing, each Party's legal
counsel may retain one (1) copy of all Confidential Information and such
documents, items and materials solely for archival purposes.

                    (d)  Confidential Information Defined. As used in this
Settlement Agreement, "Confidential Information" shall mean all secret,
confidential or proprietary information or data, whether provided in written,
oral, graphic, video, computer or other form, provided by one Party (the
"Disclosing Party") to the other Party (the "Receiving Party") pursuant to this
Settlement Agreement, the Copromotion Agreement, or that certain Mutual
Non-Disclosure Agreement between ViroPharma and Aventis, dated March 1, 2001
(the "March 2001 Confidentiality Agreement"), or generated pursuant to the
Copromotion Agreement, including, without limitation, information relating to
the Disclosing Party's existing or proposed research, development efforts,
patent applications, business or products, the terms of this Settlement
Agreement, the terms of the SaSy Agreement, and any other materials that have
not been made available by the Disclosing Party to the general public.
Notwithstanding the foregoing sentence, Confidential Information shall not
include any information or materials that:

                         (i)    were already known to the Receiving Party or its
Affiliates (other than under an obligation of confidentiality), at the time of
disclosure by the Disclosing Party to the extent such Receiving Party has
documentary evidence to that effect;

                         (ii)   were generally available to the public or
otherwise part of the public domain at the time of its disclosure to the
Receiving Party or its Affiliates;

                         (iii)  became generally available to the public or
otherwise part of the public domain after its disclosure or development, as the
case may be, and other than through any act or omission of a Party or its
Affiliates in breach of such Party's or such Party's Affiliates confidentiality
obligations under any of the March 2001 Confidentiality Agreement, the
Copromotion Agreement or this Settlement Agreement;

                         (iv)   were disclosed to a Party or its Affiliates,
other than under an obligation of confidentiality, by a person or entity that is
not an Affiliate of such Party or such

                                      -5-

<PAGE>

Party's Affiliates who had no obligation to the Disclosing Party not to disclose
such information to others; or

                         (v)    were independently discovered or developed by or
on behalf of the Receiving Party or its Affiliates without the use of the
Confidential Information belonging to the other Party and the Receiving Party
has documentary evidence to that effect.

               7. Intellectual Work Product; Promotional Materials; Assignment.

                    (a)  Ownership of Intellectual Work Product.

                         (i)    ViroPharma Ownership. Notwithstanding anything
to the contrary contained in Section 10.1 of the Copromotion Agreement, Aventis
hereby acknowledges that ViroPharma owns all right, title and interest in
and to all of the Intellectual Work Product to the extent that it relates to VP
Compound or, VP Product, except for Intellectual Work Product relating to VP
Compound or VP Product developed by ViroPharma or employees or agents of
ViroPharma and not disclosed to Aventis pursuant to the Copromotion Agreement
("Undisclosed IWP"), but in any event Aventis shall not be entitled to use such
Undisclosed IWP in connection with VP Compounds or VP Products for the duration
of patent protection of such compound or product]. For clarity, Intellectual
Work Product not relating to VP Compound or VP Product.

                         (ii)   Delivery of Intellectual Work Product to
ViroPharma. Aventis shall, within thirty (30) days after the date of this
Settlement Agreement, deliver to ViroPharma all copies and tangible embodiments
of all of the Intellectual Work Product solely owned by ViroPharma pursuant to
Section 7(a)(i), including, without limitation all documents, records,
notebooks, files, correspondence, reports, memoranda, computer tapes, computer
discs and other storage media within Aventis' or its Affiliates' possession or
control which contain any Intellectual Work Product. Aventis shall not retain
any copies of any of the Intellectual Work Product solely owned by ViroPharma
pursuant to Section 7(a)(i), except that Aventis' legal counsel may retain one
(1) copy of the Intellectual Work Product solely for archival purposes.

                    (b)  Ownership and Return of Promotional Materials.

                         (i)    ViroPharma Ownership. Notwithstanding anything
to the contrary contained in Section 10.4 of the Copromotion Agreement, Aventis
hereby acknowledges that ViroPharma owns all right, title and interest in and to
all of the Promotional Materials.

                         (ii)   Delivery of Promotional Materials to ViroPharma.
Aventis shall, within thirty (30) days after the date of this Settlement
Agreement, deliver to ViroPharma at least one copy of all Promotional Materials,
communication materials, marketing plans and reports and other materials related
to the promotion of VP Product, that Aventis or its Affiliates have in their
possession on the date of this Settlement Agreement and shall confirm that it
has destroyed all other copies thereof.

                                      -6-

<PAGE>

                         (iii)  Return of Promotional Materials relating to
Aventis Products. ViroPharma shall, by October 1, 2002, return to Aventis all
promotional materials, communication materials, marketing plans and reports and
other materials related to the Aventis Products or the Detailing of Aventis
Products and that are still in ViroPharma's possession as of September 1, 2002,
except that ViroPharma and/or VCO shall be entitled to retain for accounting
purposes one copy of any such materials, plans or reports related to amounts
billed to Aventis for Details and Calls performed by ViroPharma or VCO under the
Copromotion Agreement or this Settlement Agreement.

                    (c)  Assignment of Certain Intellectual Work Product and
Promotional Materials. Aventis hereby irrevocably assigns and transfers to
ViroPharma all of Aventis' right, title, goodwill, and interest in and to (i)
all of the Intellectual Work Product that shall be in ViroPharma's sole
ownership pursuant to Section 7(a)(i) above (whether reduced to a written form
or otherwise and whether or not patentable and without regard to form or
medium), and (ii) all of the Promotional Materials, in each case, together with
all copies and tangible embodiments thereof, under all United States and foreign
copyright, patent, trade secret and trademark laws and all other United States
and foreign laws providing for the protection of intellectual property or
similar rights. Aventis shall, at ViroPharma's expense, assist ViroPharma in
acquiring and maintaining copyright, patent, trade secret, trademark, and other
analogous intellectual property protection upon, and confirming ViroPharma's
title to, the Intellectual Work Product and Promotional Materials. Aventis'
assistance shall include, without limitation, signing all applications and any
other documents and instruments, cooperating in legal proceedings and taking
such other actions as ViroPharma considers reasonably necessary or desirable to
effectuate more fully the intents and purposes of this Section 7. In the event
Aventis does not cooperate on or sign any of the documents referenced in the
preceding sentence, or provide a explanation for not doing so within a
reasonable period, in no event to exceed forty-five (45) business days, after
ViroPharma's request therefor, Aventis hereby designates and appoints ViroPharma
and its duly authorized officers and agents as Aventis' agent and
attorney-in-fact, to act for and in its behalf and stead to execute and file any
such documents and to do all other lawfully permitted acts to further the
prosecution and issuance of any such copyright, patent, trade secret, trade
mark, or other analogous protection, with the same legal force and effect as if
executed by Aventis. The foregoing power of attorney is coupled with an interest
and shall be irrevocable

               8. Return of Samples.

                    (a)  VP Product. Within thirty (30) days after the date of
this Settlement Agreement, Aventis shall return to ViroPharma, or otherwise
dispose of in accordance with instructions from ViroPharma, all remaining VP
Product and Samples of VP Product and provide ViroPharma with a written
certified statement that all such remaining samples have either been returned or
properly disposed of and that Aventis and its Affiliates are no longer in
possession or control of any such VP Product or samples in any form or fashion.

                    (b)  Aventis Product. By August 31, 2002, ViroPharma shall
have the ViroPharma and/or VCO sales representatives conduct a physical
inventory of Samples of Aventis Product, the results of which shall be
transmitted to Aventis by September 3, 2002. ViroPharma shall conduct a
reconciliation of all Aventis Product, and Samples of Aventis

                                      -7-

<PAGE>

Product held by ViroPharma or VCO, or the employees of ViroPharma or VCO, as
applicable, on August 31, 2002. By September 30, 2002, ViroPharma shall have
audited any sales representative whose inventory reconciliation falls outside
Aventis' sample variance tolerances and shall provide the results of such
reconciliation and audit to Aventis. ViroPharma shall return to Aventis, or
otherwise dispose of in accordance with instructions from Aventis, all Aventis
Product and Samples of Aventis Product in the possession of ViroPharma or VCO or
the employees of ViroPharma or VCO as of September 1, 2002, by September 16,
2002, and provide Aventis with a written certified statement that all such
remaining Samples have either been returned or properly disposed of and that
ViroPharma and VCO are no longer in possession or control of any such Aventis
Product or Samples of Aventis Products in any form or fashion.

               9. Representations and Warranties.

                    (a)  By ViroPharma and VCO. ViroPharma and VCO, as
applicable, hereby represent and warrant to Aventis as follows:

                         (i)    Existence; Good Standing. Each of ViroPharma and
VCO is a corporation duly organized, validly existing and in good standing under
the laws of the State of Delaware and has full corporate power and authority and
legal right to execute, deliver and perform this Settlement Agreement.

                         (ii)   Due Authorization; Noncontravention. Each of
ViroPharma's and VCO's execution, delivery and performance of this Settlement
Agreement has been duly authorized by all corporate action required to be taken
on the part of ViroPharma and VCO, as applicable, and will not violate, conflict
with or result in a default (with or without notice or lapse of time or both)
under (A) ViroPharma's or VCO's charter or bylaws, as applicable, (B) any law,
rule or regulation applicable to ViroPharma or VCO or any of their respective
properties, as applicable, (C) any provision of any order, injunction, judgment
or decree of any court or governmental instrumentality entered against or
binding upon ViroPharma or VCO or any of their respective properties, as
applicable, or (D) any material mortgage, indenture, contract or agreement or
instrument to which ViroPharma or VCO, as applicable, is a party or by which
ViroPharma or VCO or any of their respective properties, as applicable, is
legally bound.

                         (iii)  Enforceability. This Settlement Agreement is a
legal, valid and binding obligation of ViroPharma and VCO, as applicable,
enforceable against ViroPharma and VCO, as applicable, in accordance with its
terms.

                         (iv)   Ownership of Released Claims. Neither ViroPharma
nor VCO has assigned any part of the claims subject to the settlement and
releases provided for by ViroPharma and VCO in this Settlement Agreement, and no
party that is not bound by this Settlement Agreement owns any interest in any of
such claims.

                         (v)    Disclosure of Material Intellectual Work
Product. ViroPharma does not have in its possession any material Intellectual
Work Product that it has not disclosed to Aventis under the Copromotion
Agreement, and ViroPharma has complied with its

                                      -8-

<PAGE>

obligations under the Copromotion Agreement to disclose material Intellectual
Work Product to Aventis.

                    (b)  By Aventis. Aventis hereby represents and warrants to
Aventis as follows:

                         (i)    Existence and Good Standing. Aventis is a
corporation duly organized, validly existing and in good standing under the laws
of the State of Delaware and has full corporate power and authority and legal
right to execute, deliver and perform this Settlement Agreement.

                         (ii)   Due Authorization; Noncontravention. Aventis'
execution, delivery and performance of this Settlement Agreement has been duly
authorized by all corporate action required to be taken on the part of Aventis
and will not violate, conflict with or result in a default (with or without
notice or lapse of time or both) under (A) Aventis' charter or bylaws, (B) any
law, rule or regulation applicable to Aventis or any of its properties, (C) any
provision of any order, injunction, judgment or decree of any court or
governmental instrumentality entered against or binding upon Aventis or any of
its properties, or (D) any material mortgage, indenture, contract or agreement
or instrument to which Aventis is a party or by which Aventis or any of its
properties is legally bound.

                         (iii)  Enforceability. This Settlement Agreement is a
legal, valid and binding obligation of Aventis, enforceable against Aventis in
accordance with its terms.

                         (iv)   Ownership of Released Claims. Aventis has not
assigned any part of the claims subject to the settlement and releases provided
for by Aventis in this Settlement Agreement, and no party that is not bound by
this Settlement Agreement owns any interest in any of such claims.

                         (v)    Intellectual Work Product; Promotional
Materials.

                                (A) Aventis does not have in its possession any
material Intellectual Work Product that it has not disclosed to ViroPharma under
the Copromotion Agreement, and Aventis has complied with its obligations under
the Copromotion Agreement to disclose material Intellectual Work Product to
ViroPharma.

                                (B) Aventis owns and has good and valid title to
Aventis' interest in the Intellectual Work Product that shall be solely owned by
ViroPharma pursuant to Section 7(a)(i) above and in the Promotional Materials,
free and clear of all encumbrances. Neither Aventis nor any of Aventis'
Affiliates has filed any patent, copyright or trademark registrations with
respect to, or applications to register, any of the Intellectual Work Product or
any of the Promotional Materials in any country or jurisdiction.

                    (c)  Survival of Representations and Warranties. The
respective rights of the Parties to assert any claim for indemnification under
Section 10(b)(i) and Section 10(c)(i) of this Settlement Agreement for breach
of any of the representations and warranties of the other Party contained in
this Section 9 shall survive the execution and delivery of this Settlement
Agreement for a period (the "Survival Period") beginning on the date of this
Settlement

                                      -9-

<PAGE>

Agreement and ending on the thirtieth (30/th/) day after the expiration of the
statute of limitations applicable to the subject matter addressed under the
relevant representation and warranty (the "Survival Period"), and thereafter
shall terminate and expire, except with respect to liabilities for any item as
to which, on or before the close of business on the last day of the Survival
Period, a Party shall have asserted a claim in writing against the other Party,
in which case, the liability for such claim shall continue until it shall have
been finally settled or adjudicated.

               10. Indemnification.

                    (a)  Indemnification of Pre-Termination Third Party Claims.
Sections 15.1, 15.2, 15.3, 15.4, and 15.6 of the Copromotion Agreement, shall
survive the termination of the Copromotion Agreement solely with respect to
claims brought by parties other than ViroPharma, Aventis, or either of their
Affiliates, except for any such claims relating to VP Compound or VP Product
brought by SaSy, its successors or assigns, based on events occurring before the
date of this Settlement Agreement.

                    (b)  Indemnification by ViroPharma and VCO. ViroPharma and
VCO shall indemnify and hold harmless Aventis and any of Aventis' Affiliates and
each of their respective shareholders, directors, officers, agents and employees
(collectively, "Aventis Indemnified Persons") from and against any and all
losses, costs, claims, liabilities, demands, fines, judgments, penalties,
damages and expenses, including reasonable attorneys' fees and expenses
(collectively, the "Losses") that the Aventis Indemnified Person may be required
to pay one or more persons or entities other than any Aventis Affiliate arising
out of or resulting from:

                         (i)    any breach of any of the representations or
warranties made by ViroPharma and VCO, respectively, in Section 9(a) of this
Settlement Agreement;

                         (ii)   any breach by ViroPharma or VCO, respectively,
of any of the covenants or agreements made by ViroPharma and VCO in this
Settlement Agreement[;

                         (iii)  VP Compound or VP Product in any way, including,
without limitation, claims relating to death or personal injury;

                         (iv)   any material misrepresentation or failure to
disclose information concerning the development or commercialization of VP
Compound or VP Product by ViroPharma;

except, in each case, to the extent caused by the negligence, recklessness, or
willful misconduct of an Aventis Indemnified Person.

                    (c)  Indemnification by Aventis. Aventis shall indemnify and
hold harmless ViroPharma and VCO and any of ViroPharma's and VCO's respective
Affiliates and each of their respective shareholders, directors, officers,
agents and employees (collectively, "ViroPharma Indemnified Persons") from and
against any and all Losses that the ViroPharma Indemnified Person may be
required to pay one or more persons or entities other than any ViroPharma
Affiliate arising out of or resulting from:

                                      -10-

<PAGE>

                         (i)    any breach of any of the representations or
warranties made by Aventis, respectively, in Section 9(b) of this Settlement
Agreement;

                         (ii)   any breach by Aventis of any of the covenants or
agreements made by Aventis in this Settlement Agreement;

                         (iii)  Aventis Product in any way, including, without
limitation, claims relating to death or personal injury; and

                         (iv)   any infringement of any issued patents based on
the use or Detailing of Aventis Product;

except, in each case, to the extent caused by the negligence, recklessness, or
willful misconduct of a ViroPharma Indemnified Person.

                    (d)  Procedures.

                         (i)    After receipt by any Aventis Indemnified Party
or any ViroPharma Indemnified Party, as applicable (the "Indemnified Party") of
any claim in respect of which such Indemnified Party will seek indemnification
from the Party required to provide such indemnification under this Section 10
(the "Indemnifiying Party"), the Indemnified Party must, as a condition to the
Indemnified Party's right to indemnification under this Section 10, provide
prompt written notice thereof to the Indemnifying Party (the "Claim Notice");
provided that any delay in providing such Claim Notice shall not relieve the
Indemnifiying Party from any liability that it may have to the Indemnified Party
under this Section 10 except to the extent that the Indemnified Party is
materially prejudiced by such delay. The Claim Notice shall (A) specify in
reasonable detail and in good faith the nature of the claim, (B) specify the
amount or in good faith the estimate of the Losses being asserted and (C) state
the basis under this Settlement Agreement for seeking such indemnification. In
no event (whether or not the Indemnified Party is controlling the defense,
compromise or settlement of such claim) will the Indemnified Party admit any
responsibility or liability with respect to any such claim and the Indemnifying
Party shall have no liability to the Indemnified Party with respect to such
claim if the Indemnified Party makes any such admission.

                         (ii)   Subject to Section 10(d)(iii) and Section
10(d)(iv) of this Settlement Agreement, the Indemnifying Party may undertake the
defense, compromise and settlement of such claim by representatives of its own
choosing reasonably acceptable to the Indemnified Party. The assumption of the
defense, compromise and settlement of any such claim by the Indemnifying Party
shall not be an acknowledgment of the obligation of the Indemnifying Party to
indemnify such Indemnified Party with respect to such claim. If the Indemnified
Party desires to participate in, but not control, any such defense, compromise
and settlement, it may do so at its sole cost and expense. The Indemnified Party
shall have the right to undertake the defense, and, subject to Section
10(d)(iii) and Section 10(d)(iv) of this Settlement Agreement, compromise and
settlement of such claim with counsel of its own choosing, and the costs and
expenses of the Indemnified Party in connection therewith shall be included as a
part of the indemnification obligations of the Indemnifying Party under this
Section

                                      -11-

<PAGE>

10, unless the Indemnifying Party, within thirty (30) days (or in the case of
litigation, fifteen (15) days) after written notice of such claim has been given
to the Indemnifying Party by the Indemnified Party, both: (i) expressly
acknowledges in writing to the Indemnified Party that that, as between the
Indemnified Party and the Indemnifying Party, the Indemnifying Party shall be
solely obligated to satisfy or discharge the obligations set forth in the Claim
Notice, and (ii) takes all reasonable and appropriate steps to affirmatively
undertake the defense of such claim.

                         (iii)  Notwithstanding the provisions of Section
10(d)(ii) of this Settlement Agreement to the extent that (A) any claim or the
litigation or resolution thereof (x) seeks an equitable remedy, or (y) is
asserted against both the Indemnifying Party and the Indemnified Party and the
Indemnified Party reasonably concludes that there are defenses available to
Indemnified Party which are different or additional to those of the Indemnifying
Party, or (B) upon petition by the Indemnified Party, an appropriate court rules
that the Indemnifiying Party failed or is failing to defend such claim
diligently, then the Indemnified Party shall have the right to control the
defense, and subject to Section 10(d)(iv) of this Settlement Agreement, the
compromise and settlement of such claim and the costs and expenses of the
Indemnifying Party in connection therewith shall be included as part of the
indemnification obligations of the Indemnifying Party under this Section 10. If
the Indemnified Party elects to exercise such right, then the Indemnifying Party
shall have the right to participate in, but not control, the defense, compromise
and settlement of such claim at the Indemnifying Party's sole cost and expense.

                         (iv)   Neither the Indemnified Party nor the
Indemnifying Party shall settle or compromise any such claim, regardless of
whether it is controlling the defense, settlement or compromise thereof without
the prior written consent of the other (which consent shall not be unreasonably
withheld, delayed or conditioned).

                         (v)    At the expense of the Indemnifying Party, the
Indemnifying Party and the Indemnified Party shall cooperate with and render to
each other such assistance as may reasonably be requested in order to insure the
proper and adequate defense of any such claim or proceeding which assistance
shall include making appropriate personnel reasonably available for any
investigation, discovery, hearing or trial.

               11.  Miscellaneous.

                    (a)  Expenses. Each of the Parties shall each pay their own
respective fees, expenses and disbursements, including the fees and expenses of
their respective counsel, accountants and other experts, in connection with the
subject matter of this Settlement Agreement and all other costs and expenses
incurred in performing and complying with all obligations to be performed under
this Settlement Agreement.

                    (b)  Specific Performance. Without limiting the rights and
remedies available to the respective Parties, whether under this Settlement
Agreement, at law, in equity or otherwise, all of which shall be cumulative,
each Party acknowledges that damages at law will be an insufficient remedy in
view of the irrevocable harm which will be suffered if such Party violates such
Party's covenants and obligations under this Settlement Agreement, and such
Party

                                      -12-

<PAGE>

agrees that the other Parties may apply in any court of competent jurisdiction
for, and shall be entitled as a matter of right to, injunctive relief
specifically to enforce any of such obligations upon the breach or threatened
breach of any such provision.

                    (c)  Publicity.

                         (i)    The Parties will consult with each other and
provide the other with the opportunity to review the portions of any completed
proposed press release or other written public statement, other than the Press
release agreed among the Parties and issued on August 1, 2002, concerning any
terms or conditions of this Settlement Agreement or the transactions
contemplated hereunder before issuing such press release or making such public
statement unless such consultation is not timely feasible in light of the
requirements of applicable law or any applicable stock exchange or NASDAQ
regulations, and no Party shall issue any such press release or make any such
public statement regarding any of the terms of conditions of this Settlement
Agreement or the transactions contemplated by this Settlement Agreement without
the consent of the other Party, except as may be required by applicable law or
any applicable stock exchange or NASDAQ regulations.

                         (ii)   Aventis acknowledges that ViroPharma will file
this Settlement Agreement with the Securities and Exchange Commission (the
"SEC") and agrees that such filing shall not be a breach of this Settlement
Agreement.

                         (iii)  Aventis acknowledges that ViroPharma will
provide a copy of this Settlement Agreement to SaSy and agrees that ViroPharma
will not be in breach of this Settlement Agreement by doing so.

                    (d)  Voluntary Act; No Reliance. Each of the Parties is
entering into this Settlement Agreement voluntarily, without duress or undue
influence. Each of the Parties acknowledges that (i) such Party has been
represented in the negotiations for, and in the preparation of this Settlement
Agreement by counsel or other professionals of their own respective choice, (ii)
such Party has read this Settlement Agreement and has had this Settlement
Agreement fully explained to it by such counsel or professionals, (iii) that
such Party is fully aware of the contents of this Settlement Agreement and of
this Settlement Agreement's legal effect; and (iv) such Party is not relying
upon and has not relied upon any representations, warranties and statements made
by any of the other Parties in connection with such Party's execution, delivery
and performance of this Settlement Agreement other than the representations,
warranties and statements expressly made by such other Party in Section 9(a)
and Section 9(b) of this Settlement Agreement.

                    (e)  Amendment, Severability, Parties in Interest. This
Settlement Agreement may be amended, modified or supplemented only by a written
instrument duly executed by each of the Parties. If any provision of this
Settlement Agreement shall for any reason be held to be invalid, illegal or
unenforceable in any respect, such invalidity, illegality or unenforceability
shall not affect any other provision hereof, and this Settlement Agreement shall

                                      -13-

<PAGE>

be construed as if such invalid, illegal or unenforceable provision had never
been contained herein. This Settlement Agreement shall be binding upon and inure
to the benefit of and be enforceable by the successors and assigns of the
Parties. Nothing in this Settlement Agreement, express or implied, is intended
to confer on any Person other than: (i) the Parties, (ii) the Aventis Parties
with respect to ViroPharma's release under Section 3(a) of this Settlement
Agreement, (iii) the Aventis Indemnified Parties with respect to ViroPharma's
and VCO's indemnification obligations under Section 10 of this Settlement
Agreement, (iii) the ViroPharma Parties with respect to Aventis' release under
Section 3(b) of this Settlement Agreement, and (iv) the ViroPharma Indemnified
Parties with respect to Aventis' indemnification obligations under Section 10 of
this Settlement Agreement, and or their respective successors and assigns,
heirs, administrators and personal representatives, any rights, remedies,
obligations or liabilities under or by reason of this Settlement Agreement.

                    (f)  Waivers. Any term or provision of this Settlement
Agreement may be waived at any time by the Party entitled to the benefit thereof
by a written instrument expressly stated to be a waiver and duly executed by
such Party. The failure of any Party at any time or times to require performance
of any provision of this Settlement Agreement shall in no manner affect the
right of such Party at a later time to enforce the same or any other provision
of this Settlement Agreement. The waiver of any condition or of the breach of
any provision of this Settlement Agreement in one or more instances shall not
operate or be construed as a waiver of any other condition or subsequent breach.

                    (g)  Notices. All notices that are required or permitted
under this Settlement Agreement shall be in writing and shall be deemed
sufficiently given if: (i) sent by registered or certified mail, return receipt
requested, proper postage prepaid, (ii) by reputable overnight delivery service,
proper charges prepaid, or (iii) by facsimile (with a copy sent by any of the
methods of delivery described in clauses (i) or (ii) above within twenty-four
(24) hours after sending by facsimile). Any notices shall be deemed received (A)
the third business day after the date when sent by registered or certified mail,
return receipt requested, (B) the business day after the date when sent by
reputable overnight delivery service, and (C) the day sent when sent by
facsimile (provided, that the Party sending the notice by facsimile sends such
notice pursuant to any of the methods of delivery described in clauses (i) or
(ii) above with twenty-four (24) hours after sending by facsimile), in each
case, to the address set forth below, unless such address is changed by notice
given in accordance with this Section 11(g):

       If to ViroPharma or VCO,   ViroPharma Incorporated
       to:                        405 Eagleview Boulevard
                                  Exton, PA 19341
                                  Facsimile No.: 610-458-2017
                                  Attention: Vice President and General Counsel

                                      -14-

<PAGE>

       If to Aventis, to:          Aventis Pharmaceuticals Inc.
                                   200 Crossing Boulevad
                                   P.O. Box 6890
                                   Bridgewater, NJ 08807-0890, U.S.A.
                                   Facsimile: 908-231-4480
                                   Attention: Vice President, Legal Corporate
                                   Development

                    (h)  Entire Agreement. This Settlement Agreement (including
the Schedules to this Settlement Agreement), sets forth the entire agreement and
understanding of the Parties hereto with respect to the matters set forth in
this Settlement Agreement and supersedes all prior agreements or understandings,
oral and written, among the Parties or otherwise with respect to such matters.

                    (i)  Governing Law. This Settlement Agreement shall be
governed by and construed in accordance with the law of the Commonwealth of
Pennsylvania, without regard to the conflict of law principles of Pennsylvania
or any other jurisdictions.

                    (j)  Counterparts. This Settlement Agreement may be executed
in two or more counterparts, each of which shall be binding as of the date first
written above, and all of which shall constitute one and the same instrument.
Each such copy shall be deemed an original, and it shall not be necessary in
making proof of this Settlement Agreement to produce or account for more than
one such counterpart. This Settlement Agreement shall not be effective unless
and until it has been signed by each of the Parties hereto.

                    (k)  Offset. Except for any amounts due by a Party hereto
pursuant to Sections 5(a-b) and any indemnification due for third party claims,
including, without limitation, those provided for in Section 10 of this
Settlement Agreement,

                         (i)    Aventis shall be entitled to offset any amounts
due to VCO against any amounts due from VCO or ViroPharma and offset any amounts
due to ViroPharma against any amounts due from VCO or ViroPharma, and

                         (ii)   VCO and ViroPharma shall each be entitled to
offset any amounts due to Aventis against any amounts due from Aventis.

                            [Signature Page Follows]

                                      -15-

<PAGE>

                                                                    Exhibit 10.1

               IN WITNESS WHEREOF, the Parties have caused their respective duly
authorized representatives to execute this Settlement Agreement on the date
first written above.

                                    VIROPHARMA INCORPORATED

                                    By: /s/ Michel de Rosen
                                        ----------------------------------------

                                         Michel de Rosen
                                         President, CEO & Chairman of the Board

                                    VCO INCORPORATED

                                    By: /s/ Michel de Rosen
                                        ----------------------------------------

                                         Michel de Rosen
                                         President

                                    AVENTIS PHARMACEUTICALS, INC.

                                    By: /s/ Jerry Belle
                                        ----------------------------------------

                                         Jerry Belle
                                         President and Chief Executive Officer

              [Signature Page to Settlement Agreement and Release]<PAGE>

                                                                    Exhibit 10.2

                         SALES FORCE TRANSFER AGREEMENT

               THIS SALES FORCE TRANSFER AGREEMENT (this "Transfer Agreement")
is made on this 1/st/ day of August, 2002 by and among VIROPHARMA INCORPORATED,
a Delaware corporation ("ViroPharma"), VCO INCORPORATED, a Delaware corporation
and wholly-owned subsidiary of ViroPharma ("VCO"), and AVENTIS PHARMACEUTICALS,
INC., a Delaware corporation ("Aventis"). For convenience, each of ViroPharma,
VCO and Aventis may be referred to in this Transfer Agreement as a "Party" and
collectively as "Parties."

                                   Background

               ViroPharma and Aventis are parties to that certain Copromotion
and Codevelopment Agreement, effective as of September 9, 2001, as amended (the
"Copromotion Agreement"). ViroPharma and Aventis are also parties to that
certain Stock Purchase Agreement, dated as of September 9, 2001 (the "Stock
Purchase Agreement"). Pursuant to that certain Sublicense and Subcontract
Agreement between ViroPharma and VCO, dated December 31, 2001 (the "VCO
Subcontract Agreement"), ViroPharma subcontracted and sublicensed to VCO certain
of ViroPharma's obligations and rights under the Copromotion Agreement.

               IN CONSIDERATION of developments that have occurred since the
Effective Date of the Copromotion Agreement and of the mutual covenants and
releases contained in this Transfer Agreement and for other good and valuable
consideration, the receipt and sufficiency of which are hereby acknowledged, the
Parties, intending to be legally bound, hereby agree as follows:

               1. Certain Capitalized Terms. Capitalized terms used in this
Transfer Agreement shall have the respective meanings ascribed to such terms in
the Copromotion Agreement and in this Transfer Agreement.

               2. Transfer of ViroPharma Sales Force to Aventis.

                    (a) Offers of Employment. No later than August 2, 2002,
ViroPharma shall request the consent of each of the ViroPharma and VCO employees
identified on Schedule 2(a)((alpha)) attached to this Transfer Agreement
(collectively, the "Employees") to provide a true and complete copy of the
Personnel File (as defined below) of such Employee to Aventis, which consent
shall be due to ViroPharma by August 7, 2002. No later than August 9, 2002,
provided ViroPharma has received such consent of an Employee, ViroPharma shall
provide Aventis with a copy of such Employee's Personnel File. No later than
five (5) business days after receiving Personnel Files from ViroPharma, Aventis
will offer employment without an advance hiring interview to each Employee.

                        (i)  For whom Aventis has received a true and complete
copy of such Employee's Personnel File, and

<PAGE>

                        (ii)  Whose Personnel File or other documents provided
to Aventis pursuant to this Section 2 do not document disciplinary action taken
by ViroPharma or VCO against such Employee for gross misconduct, dishonesty,
fraud, deceit, or unlawful discrimination by such Employee, and

                        (iii) Who has received a Bachelor's Degree or
equivalent,

such employment to become effective as of September 1, 2002 (the "Effective
Hiring Date"), provided however, that the date that Aventis shall offer
employment to an Excepted Employee as defined below shall be five (5) business
days after such Excepted Employee returns to work with ViroPharma from a leave
of absence as Aventis is notified by ViroPharma, and the effective date of such
Excepted Employee's hiring by Aventis shall be on the first Monday no more than
three (3) weeks after the date on which such Excepted Employee accepts Aventis'
offer of employment. "Excepted Employee" shall mean any Employee who is on
short-term disability leave or any other leave of absence on the Effective
Hiring Date. Aventis' employment offer letter shall reference Aventis' standard
pre-employment conditions, as listed in Schedule 2(a)((beta)), which any
employment candidate must satisfy as a condition of employment with Aventis.

Notwithstanding anything to the contrary in this Section 2, Aventis shall make
such employment offers in compliance with all applicable laws, rules and
regulations. Additionally, Aventis shall use commercially reasonable efforts to
ensure that no more than five percent (5%) of Employees shall receive offers of
employment that would require them to relocate if they were to accept such
offer.

As used in this Section 2, the term "Personnel File" shall mean an employee's
personnel file, and if applicable, a manager's working file, excluding, in each
case, any medical or health information regarding such employee, but including
an electronic file containing the information set forth in Schedule 2(a)(x).

                    (b) Transferred VCO Employees. Each Employee who accepts
employment with Aventis pursuant to the employment offer letter shall be
referred to in this Transfer Agreement as a "Transferred VCO Employee." Aventis
shall hire each Transferred VCO Employee with the same level of responsibility
and base salary as such Transferred VCO Employee had at ViroPharma or VCO on the
date of this Transfer Agreement. Aventis shall not take any action so as to
require any compliance under the Worker Adjustment and Retraining Notification
Act or similar state or local laws until the date immediately succeeding the
Effective Hiring Date. With respect to each Transferred VCO Employee, Aventis
will recognize the service of any Transferred VCO Employee with ViroPharma and
VCO, as applicable, prior to the Effective Hiring Date, for purposes of
eligibility for, participation in and early commencement of (i) benefits, and
(ii) vesting of retirement plans, including, without limitation, eligibility for
an amount of severance, provided that the crediting of service does not result
in the duplication of benefits.

                    (c) Aventis Obligations Regarding Employees and Transferred
VCO Employees. Aventis shall not assume any responsibility for any commitment,
obligation, duty or liability of ViroPharma or VCO to any Transferred VCO
Employee and to any Employee who is not a Transferred VCO Employee that arises
as a result of such Transferred VCO Employee's or Employees' employment with
ViroPharma or VCO, as applicable, or the cessation of such employment including,
without limitation, accrued, but unused vacation, sick leave or other paid time
off, accrued but unpaid taxes, all other accrued but unpaid amounts payable
pursuant to

                                      -2-

<PAGE>

Employee's employment by ViroPharma until the Effective Hiring Date, severance
obligations, or breach by ViroPharma of applicable laws or regulations if any
(collectively, the "Retained Employee Obligations"). Neither VCO nor ViroPharma
shall assume any responsibility for any commitment, duty or liability of Aventis
that arises as a result of Aventis' making of offers of employment or refraining
from making offers of employment (unless, in the latter case, pursuant to
Section 2(a) of this Transfer Agreement) to the Employees or any Transferred VCO
Employee's employment with Aventis (collectively, the "Aventis Transferred VCO
Employee Obligations") except as provided in Section 5 (a) below.

                    (d) ViroPharma and VCO Obligations Regarding Employees and
Transferred VCO Employees. ViroPharma and VCO, as applicable, shall, until the
Effective Hiring Date:

                        (i)   Maintain personnel in the positions currently held
by Mike Kelly, George Lauderback, Kerry Clem, Susan Schiller, Nancy Shanfelt,
and Margaret LaPree responsible for the management of the sales force and the
sales force support services, including Sample management;

                        (ii)  Communicate no information to the Employees
concerning the potential transfer of the Employees to Aventis that has not been
previously approved by Aventis;

                        (iii) Plan with Aventis communications to be made by
ViroPharma or VCO to its sales force and sales management and by Aventis to its
sales force concerning the potential transfer of the Employees to Aventis;

                        (iv)  Hold regular meetings to communicate with the
Employees regarding the potential transfer of the Employees to Aventis;

                        (v)   Transmit to the Employees documents received from
Aventis regarding the potential transfer of the Employees to Aventis;

                        (vi)  provide to Aventis, together with the Personnel
File of each Employee that has agreed to the transfer of a copy of its Personnel
File to Aventis, a verification of the hiring date by ViroPharma or VCO of such
Employee; and

                        (vii) use commercially reasonable efforts to assist
Aventis in good faith in Aventis' efforts to employ the Employees as described
herein.

               3. Consideration. In consideration for ViroPharma's and VCO's
consent to and assistance in Aventis' offering employment to the Employees
pursuant to Section 2, Aventis shall pay VCO fifteen million, four hundred ten
thousand U.S. dollars ($15,410,000) due immediately on the date of this Transfer
Agreement.

               4. Representations and Warranties.

                    (a) By ViroPharma and VCO. ViroPharma and VCO, as
applicable, hereby represent and warrant to Aventis as follows:

                                      -3-

<PAGE>

                        (i)   Existence; Good Standing. Each of ViroPharma and
VCO is a corporation duly organized, validly existing and in good standing under
the laws of the State of Delaware and has full corporate power and authority and
legal right to execute, deliver and perform this Transfer Agreement.

                        (ii)  Due Authorization; Noncontravention. Each of
ViroPharma's and VCO's execution, delivery and performance of this Transfer
Agreement has been duly authorized by all corporate action required to be taken
on the part of ViroPharma and VCO, as applicable, and will not violate, conflict
with or result in a default (with or without notice or lapse of time or both)
under (A) ViroPharma's or VCO's charter or bylaws, as applicable, (B) any law,
rule or regulation applicable to ViroPharma or VCO or any of their respective
properties, as applicable, (C) any provision of any order, injunction, judgment
or decree of any court or governmental instrumentality entered against or
binding upon ViroPharma or VCO or any of their respective properties, as
applicable, or (D) any material mortgage, indenture, contract or agreement or
instrument to which ViroPharma or VCO, as applicable, is a party or by which
ViroPharma or VCO or any of their respective properties, as applicable, is
legally bound.

                        (iii) Enforceability. This Transfer Agreement is a
legal, valid and binding obligation of ViroPharma and VCO, as applicable,
enforceable against ViroPharma and VCO, as applicable, in accordance with its
terms.

                        (iv)  Complete Personnel Files. The Personnel File to be
provided to Aventis by ViroPharma for each Employee who has consented to the
supply of a copy of such file to Aventis will be a true and complete copy of
such Personnel File, and ViroPharma will provide Aventis with all documentation
concerning any disciplinary action taken by ViroPharma or VCO against such
Employee for gross misconduct, dishonesty, fraud, deceit, or unlawful
discrimination by such Employee.

                        (v)   Employment Claims. ViroPharma will notify Aventis
in writing of any ongoing harassment or discrimination claims against ViroPharma
brought by any Employee or brought against an Employee by ViroPharma, or by
another Employee, but in such latter case, only to the extent actually known to
the members of the management team of ViroPharma, as listed in ViroPharma's 10K
for the year ended December 31, 2001, who are employed by ViroPharma on the date
of this Transfer Agreement, or of VCO.

                        (vi)  Neither of the members of the management team of
ViroPharma, as listed in ViroPharma's 10K for the year ended December 31, 2001,
who are employed by ViroPharma on the date of this Transfer Agreement, nor any
duly elected of VCO have any actual knowledge of any reason why an Employee's
employment at ViroPharma should be discontinued absent this Transfer Agreement,
or why Aventis should not offer an Employee employment with Aventis.

                        (vii) All Employees, within the last twelve (12)
calendar months took and passed a drug screen and were determined to, have an
acceptable driving record as documented by DMV (Department of Motor Vehicle)
records.

                                      -4-

<PAGE>

                        (viii) None of the Employees has, to the best of
ViroPharma's or VCO's knowledge, had Debarment or Exclusion Proceedings
instituted against them at any time.

                    (b) By Aventis. Aventis hereby represents and warrants to
Aventis as follows:

                        (i)    Existence and Good Standing. Aventis is a
corporation duly organized, validly existing and in good standing under the laws
of the State of Delaware and has full corporate power and authority and legal
right to execute, deliver and perform this Transfer Agreement.

                        (ii)   Due Authorization; Noncontravention. Aventis'
execution, delivery and performance of this Transfer Agreement has been duly
authorized by all corporate action required to be taken on the part of Aventis
and will not violate, conflict with or result in a default (with or without
notice or lapse of time or both) under (A) Aventis' charter or bylaws, (B) any
law, rule or regulation applicable to Aventis or any of its properties, (C) any
provision of any order, injunction, judgment or decree of any court or
governmental instrumentality entered against or binding upon Aventis or any of
its properties, or (D) any material mortgage, indenture, contract or agreement
or instrument to which Aventis is a party or by which Aventis or any of its
properties is legally bound.

                        (iii)  Enforceability. This Transfer Agreement is a
legal, valid and binding obligation of Aventis, enforceable against Aventis in
accordance with its terms.

                    (c) Survival of Representations and Warranties. The
respective rights of the Parties to assert any claim for indemnification under
Section 5(b) and Section 5(c) of this Transfer Agreement for breach of any of
the representations and warranties of the other Party contained in this Section
4 shall survive the execution and delivery of this Transfer Agreement for a
period beginning on the date of this Transfer Agreement and ending on the
thirtieth (30th) day after the expiration of the statute of limitations
applicable to the subject matter addressed under the relevant representation and
warranty (the "Survival Period"), and thereafter shall terminate and expire,
except with respect to liabilities for any item as to which, on or before the
close of business on the last day of the Survival Period, a Party shall have
asserted a claim in writing against the other Party, in which case, the
liability for such claim shall continue until it shall have been finally settled
or adjudicated.

               5. Indemnification.

                    (a) Indemnification for Certain Severance Payments by
ViroPharma and/or VCO. ViroPharma and/or VCO, as applicable, shall indemnify
Aventis for any severance paid pursuant to Aventis' Transition Assistance Plan
attached hereto as Schedule 5(a) for up to five (5) Area Business Managers
listed on Schedule 2(a)((alpha)) and employed by Aventis as a result of this
Transfer Agreement, if Aventis terminates the employment of such Area Business
Manager by March 31, 2003, due to performance problems. ViroPharma and/or VCO
shall pay severance to Scott Wisneski, according to ViroPharma's severance
policies if Scott Wisneski, declines to accept Aventis' offer of employment in
Cleveland, OH.

                                      -5-

<PAGE>

               (b)  Indemnification by ViroPharma and VCO. ViroPharma and/or
VCO, as applicable, shall indemnify and hold harmless Aventis and any of
Aventis' Affiliates and each of their respective shareholders, directors,
officers, agents and employees (collectively, "Aventis Indemnified Persons")
from and against any and all losses, costs, claims, liabilities, demands, fines,
judgments, penalties, damages and expenses, including reasonable attorneys' fees
and expenses (collectively, the "Losses") that the Aventis Indemnified Person
may be required to pay one or more persons or entities other than any Aventis
Affiliate arising out of or resulting from: (i) any breach of any of the
representations or warranties made by ViroPharma and VCO, respectively, in
Section 4(a) of this Transfer Agreement; (ii) any breach by ViroPharma or VCO,
respectively, of any of the covenants or agreements made by ViroPharma and VCO
in this Transfer Agreement; and (iii) any of the Retained Employee Obligations.

               (c)  Indemnification by Aventis. Aventis shall indemnify and hold
harmless ViroPharma and VCO and any of ViroPharma's and VCO's respective
Affiliates and each of their respective shareholders, directors, officers,
agents and employees (collectively, "ViroPharma Indemnified Persons") from and
against any and all Losses that the ViroPharma Indemnified Person may be
required to pay one or more persons or entities other than any ViroPharma
Affiliate arising out of or resulting from: (i) any breach of any of the
representations or warranties made by Aventis, respectively, in Section 4(b) of
this Transfer Agreement; and (ii) any breach by Aventis of any of the covenants
or agreements made by Aventis in this Transfer Agreement; (iii) any of the
Aventis Transferred VCO Employee Obligations.

               (d)  Procedures.

                    (i)   After receipt by any Aventis Indemnified Party or any
ViroPharma Indemnified Party, as applicable (the "Indemnified Party") of any
claim in respect of which such Indemnified Party will seek indemnification from
the Party required to provide such indemnification under this Section 5 (the
"Indemnifiying Party"), the Indemnified Party must, as a condition to the
Indemnified Party's right to indemnification under this Section 5, provide
prompt written notice thereof to the Indemnifying Party (the "Claim Notice");
provided that any delay in providing such Claim Notice shall not relieve the
Indemnifiying Party from any liability that it may have to the Indemnified Party
under this Section 5 except to the extent that the Indemnified Party is
materially prejudiced by such delay. The Claim Notice shall (A) specify in
reasonable detail and in good faith the nature of the claim, (B) specify the
amount or in good faith the estimate of the Losses being asserted and (C) state
the basis under this Transfer Agreement for seeking such indemnification. In no
event (whether or not the Indemnified Party is controlling the defense,
compromise or settlement of such claim) will the Indemnified Party admit any
responsibility or liability with respect to any such claim and the Indemnifying
Party shall have no liability to the Indemnified Party with respect to such
claim if the Indemnified Party makes any such admission.

                    (ii)  Subject to Section 5(d)(iii) and Section 5(d)(iv) of
this Transfer Agreement, the Indemnifying Party may undertake the defense,
compromise and settlement of such claim by representatives of its own choosing
reasonably acceptable to the Indemnified Party. The assumption of the defense,
compromise and settlement of any such claim by the Indemnifying Party shall not
be an acknowledgment of the obligation of the Indemnifying Party to indemnify
such Indemnified Party with respect to such claim. If the Indemnified Party

                                       -6-

<PAGE>

desires to participate in, but not control, any such defense, compromise and
settlement, it may do so at its sole cost and expense. The Indemnified Party
shall have the right to undertake the defense, and, subject to Section 5(d)(iii)
and Section 5(d)(iv) of this Transfer Agreement, compromise and settlement of
such claim with counsel of its own choosing, and the costs and expenses of the
Indemnified Party in connection therewith shall be included as a part of the
indemnification obligations of the Indemnifying Party under this Section 5,
unless the Indemnifying Party, within thirty (30) days (or in the case of
litigation, fifteen (15) days) after written notice of such claim has been given
to the Indemnifying Party by the Indemnified Party, both: (i)expressly
acknowledges in writing to the Indemnified Party that that, as between the
Indemnified Party and the Indemnifying Party, the Indemnifying Party shall be
solely obligated to satisfy or discharge the obligations set forth in the Claim
Notice, and (ii) takes all reasonable and appropriate steps to affirmatively
undertake the defense of such claim.

                    (iii)   Notwithstanding the provisions of Section 5(d)(ii)
of this Transfer Agreement to the extent that (A) any claim or the litigation or
resolution thereof (x) seeks an equitable remedy, or (y) is asserted against
both the Indemnifying Party and the Indemnified Party and the Indemnified Party
reasonably concludes that there are defenses available to Indemnified Party
which are different or additional to those of the Indemnifying Party, or (B)
upon petition by the Indemnified Party, an appropriate court rules that the
Indemnifiying Party failed or is failing to defend such claim diligently, then
the Indemnified Party shall have the right to control the defense, and subject
to Section 5(d)(iv) of this Transfer Agreement, the compromise and settlement of
such claim and the costs and expenses of the Indemnifying Party in connection
therewith shall be included as part of the indemnification obligations of the
Indemnifying Party under this Section 5. If the Indemnified Party elects to
exercise such right, then the Indemnifying Party shall have the right to
participate in, but not control, the defense, compromise and settlement of such
claim at the Indemnifying Party's sole cost and expense.

                    (iv)    Neither the Indemnified Party nor the Indemnifying
Party shall settle or compromise any such claim, regardless of whether it is
controlling the defense, settlement or compromise thereof without the prior
written consent of the other (which consent shall not be unreasonably withheld,
delayed or conditioned).

                    (v)     At the expense of the Indemnifying Party, the
Indemnifying Party and the Indemnified Party shall cooperate with and render to
each other such assistance as may reasonably be requested in order to insure the
proper and adequate defense of any such claim or proceeding which assistance
shall include making appropriate personnel reasonably available for any
investigation, discovery, hearing or trial.

          6. Miscellaneous.

               (a)  Expenses. Each of the Parties shall each pay their own
respective fees, expenses and disbursements, including the fees and expenses of
their respective counsel, accountants and other experts, in connection with the
subject matter of this Transfer Agreement and all other costs and expenses
incurred in performing and complying with all obligations to be performed under
this Transfer Agreement.

                                       -7-

<PAGE>

               (b)  Specific Performance. Without limiting the rights and
remedies available to the respective Parties, whether under this Transfer
Agreement, at law, in equity or otherwise, all of which shall be cumulative,
each Party acknowledges that damages at law will be an insufficient remedy in
view of the irrevocable harm which will be suffered if such Party violates such
Party's covenants and obligations under this Transfer Agreement, and such Party
agrees that the other Parties may apply in any court of competent jurisdiction
for, and shall be entitled as a matter of right to, injunctive relief
specifically to enforce any of such obligations upon the breach or threatened
breach of any such provision.

               (c)  Publicity.

                    (i)   The Parties will consult with each other and provide
the other with the opportunity to review the portions of any completed proposed
press release or other written public statement, other than the press release
agreed to among the Parties and issued on August 1, 2002, concerning any terms
or conditions of this Transfer Agreement or the transactions contemplated
hereunder before issuing such press release or making such public statement
unless such consultation is not timely feasible in light of the requirements of
applicable law or any applicable stock exchange or NASDAQ regulations, and no
Party shall issue any such press release or make any such public statement
regarding any of the terms of conditions of this Transfer Agreement or the
transactions contemplated by this Transfer Agreement without the consent of the
other Party, except as may be required by applicable law or any applicable stock
exchange or NASDAQ regulations.

                    (ii)  Aventis acknowledges that ViroPharma will file this
Transfer Agreement with the Securities and Exchange Commission (the "SEC") and
agrees that such filing shall not be a breach of this Transfer Agreement.

               (d)  Voluntary Act; No Reliance. Each of the Parties is entering
into this Transfer Agreement voluntarily, without duress or undue influence.
Each of the Parties acknowledges that (i) such Party has been represented in the
negotiations for, and in the preparation of this Transfer Agreement by counsel
or other professionals of their own respective choice, (ii) such Party has read
this Transfer Agreement and has had this Transfer Agreement fully explained to
it by such counsel or professionals, (iii) that such Party is fully aware of the
contents of this Transfer Agreement and of this Transfer Agreement's legal
effect; and (iv) such Party is not relying upon and has not relied upon any
representations, warranties and statements made by any of the other Parties in
connection with such Party's execution, delivery and performance of this
Transfer Agreement other than the representations, warranties and statements
expressly made by such other Party in Section 4(a) and Section 4(b) of this
Transfer Agreement.

               (e)  Amendment, Severability, Parties in Interest. This Transfer
Agreement may be amended, modified or supplemented only by a written instrument
duly executed by each of the Parties. If any provision of this Transfer
Agreement shall for any reason be held to be invalid, illegal or unenforceable
in any respect, such invalidity, illegality or

                                       -8-

<PAGE>

unenforceability shall not affect any other provision hereof, and this Transfer
Agreement shall be construed as if such invalid, illegal or unenforceable
provision had never been contained herein. This Transfer Agreement shall be
binding upon and inure to the benefit of and be enforceable by the successors
and assigns of the Parties.

               (f)  Waivers. Any term or provision of this Transfer Agreement
may be waived at any time by the Party entitled to the benefit thereof by a
written instrument expressly stated to be a waiver and duly executed by such
Party. The failure of any Party at any time or times to require performance of
any provision of this Transfer Agreement shall in no manner affect the right of
such Party at a later time to enforce the same or any other provision of this
Transfer Agreement. The waiver of any condition or of the breach of any
provision of this Transfer Agreement in one or more instances shall not operate
or be construed as a waiver of any other condition or subsequent breach.

               (g)  Notices. All notices that are required or permitted under
this Settlement Agreement shall be in writing and shall be deemed sufficiently
given if: (i) sent by registered or certified mail, return receipt requested,
proper postage prepaid, (ii) by reputable overnight delivery service, proper
charges prepaid, or (iii) by facsimile (with a copy sent by any of the methods
of delivery described in clauses (i) or (ii) above within twenty-four (24) hours
after sending by facsimile). Any notices shall be deemed received (A) the third
business day after the date when sent by registered or certified mail, return
receipt requested, (B) the business day after the date when sent by reputable
overnight delivery service, and (C) the day sent when sent by facsimile
(provided, that the Party sending the notice by facsimile sends such notice
pursuant to any of the methods of delivery described in clauses (i) or (ii)
above with twenty-four (24) hours after sending by facsimile), in each case, to
the address set forth below, unless such address is changed by notice given in
accordance with this Section 6(g):

          If to ViroPharma or VCO, ViroPharma Incorporated
          to:                      405 Eagleview Boulevard
                                   Exton, PA 19341
                                   Facsimile No.: 610-458-2017
                                   Attention: Vice President and General Counsel

          If to Aventis, to:       Aventis Pharmaceuticals Inc.
                                   200 Crossing Boulevard
                                   P.O. Box 6890
                                   Bridgewater, NJ 08807-0890, U.S.A.
                                   Facsimile: 908-231-4480
                                   Attention: Vice President, Legal Corporate
                                   Development

               (h)  Entire Agreement. This Transfer Agreement (including the
Schedules to this Transfer Agreement), sets forth the entire agreement and
understanding of the Parties hereto with respect to the matters set forth in
this Transfer Agreement and supersedes all prior agreements or understandings,
oral and written, among the Parties or otherwise with respect to such matters.

                                       -9-

<PAGE>

               (i)  Governing Law. This Transfer Agreement shall be governed by
and construed in accordance with the law of the Commonwealth of Pennsylvania,
without regard to the conflict of law principles of Pennsylvania or any other
jurisdictions.

               (j)  Counterparts. This Transfer Agreement may be executed in two
or more counterparts, each of which shall be binding as of the date first
written above, and all of which shall constitute one and the same instrument.
Each such copy shall be deemed an original, and it shall not be necessary in
making proof of this Transfer Agreement to produce or account for more than one
such counterpart. This Transfer Agreement shall not be effective unless and
until it has been signed by each of the Parties hereto.

                            [Signature Page Follows]

                                      -10-

<PAGE>

     IN WITNESS WHEREOF, the Parties have caused their respective duly
authorized representatives to execute this Transfer Agreement on the date first
written above.

                                     VIROPHARMA INCORPORATED

                                     By: /s/ Michel de Rosen
                                        ----------------------------------------
                                          Michel de Rosen
                                          President, CEO & Chairman of the Board

                                     VCO INCORPORATED

                                     By: /s/ Michel de Rosen
                                        ----------------------------------------
                                          Michel de Rosen
                                          President & CEO

                                     AVENTIS PHARMACEUTICALS, INC.

                                     By: /s/ Jerry Belle
                                        ----------------------------------------
                                          Jerry Belle
                                          President and Chief Executive Officer

                                      -11-

<PAGE>

                                                                    Exhibit 10.2

                             Schedule 2(a)((alpha))
                                    Employees

<TABLE>
<CAPTION>
     Status     Last Name              First Name                Position
     ------     ---------              ----------                --------
<S>             <C>                    <C>           <C>
PROFESSIONAL SALES REPRESENTATIVES:
-----------------------------------

     1Active    Bazirgan               Richard       Professional Sales Representative
     2Active    Sullivan               Jeffrey       Professional Sales Representative
     3Active    Bohlen                 Zachary       Professional Sales Representative
     4Active    Oczkowski              Kristine      Professional Sales Representative
     5Active    McCooey                Andrew        Professional Sales Representative
     6Active    Marin                  Christophe    Professional Sales Representative
     7Active    D'Agostino             Michael       Professional Sales Representative
     8Active    Azzone                 Christopher   Professional Sales Representative
     9Active    Tocke                  Gary          Professional Sales Representative
    10Active    DiPirro                Keith         Professional Sales Representative
    11Active    Khan                   Sana          Professional Sales Representative
    12Active    Siegell                Michelle      Professional Sales Representative
    13Active    VanDeWiele             Katherine     Professional Sales Representative
    14Active    Jacobs                 Christopher   Professional Sales Representative
    15Active    Leflein                Jason         Professional Sales Representative
    16Active    Uva                    Nicholas      Professional Sales Representative
    17Active    Fleischut              Peter         Professional Sales Representative
    18Active    Quirch                 Agustin       Professional Sales Representative
    19Active    Lauda                  Brian         Professional Sales Representative
    20Active    McNulty                Michael       Professional Sales Representative
    21Active    Rudek                  Paul          Professional Sales Representative
    22Active    Mabilia                Jodie         Professional Sales Representative
    23Active    Tubman                 John          Professional Sales Representative
    24Active    Ray                    Dori          Professional Sales Representative
    25Active    Peevy                  Janice        Professional Sales Representative
    26Active    Shade                  Jason         Professional Sales Representative
    27Active    Chopper                Julie         Professional Sales Representative
    28Active    Nedzesky               Amy           Professional Sales Representative
    29Active    Vaccarello             Diana         Professional Sales Representative
    30Active    Mushock                Gary          Professional Sales Representative
    31Active    Lind                   Eric          Professional Sales Representative
    32Active    Pollizi                Gayle         Professional Sales Representative
    33Active    Deakyne                Danielle      Professional Sales Representative
    34STD        (1) Motsco            Jeanene       Professional Sales Representative
    35Active    Bowman                 Kara          Professional Sales Representative
    36Active    Colvin                 Darren        Professional Sales Representative
    37Active    Bernardoni             Jed           Professional Sales Representative
    38Active    Kuehl                  Nancy         Professional Sales Representative
    39Active    Johnson                Eric          Professional Sales Representative
    40Active    Powell                 Shannon       Professional Sales Representative
    41Active    Rucker                 Christopher   Professional Sales Representative
    42Active    Pauley                 Rebekah       Professional Sales Representative
    43Active    Davis                  Michael       Professional Sales Representative
    44Active    Sturino                Charissa      Professional Sales Representative
    45Active    Barrow                 David         Professional Sales Representative
    46Active    Corrigan               Bernard       Professional Sales Representative
    47Active    Cripe                  Scott         Professional Sales Representative
    48Active    Spickelmier            Kristin       Professional Sales Representative
    49Active    Sharpe-Lee             Zoe           Professional Sales Representative
    50Active    Rothwell               Matthew       Professional Sales Representative
    51Active    Holder                 Derk          Professional Sales Representative
    52Active    Cwynar                 Michele       Professional Sales Representative
    53Active    Caulk                  M             Professional Sales Representative
    54Active    Swedin                 Jeremy        Professional Sales Representative
    55Active    Bender                 Matthew       Professional Sales Representative
    56Active    Jordan                 William       Professional Sales Representative
    57Active    Holmes                 Carol         Professional Sales Representative
    58Active    Rentz                  Penny         Professional Sales Representative
    59Active    Nalley                 Stephen       Professional Sales Representative
    60Active    Williams               Francee       Professional Sales Representative
    61Active    Eby                    Chris         Professional Sales Representative
    62Active    Kaplan                 Paula         Professional Sales Representative
    63Active    Puig                   Elsa          Professional Sales Representative
    64Active    Meyers                 Marlena       Professional Sales Representative
    65Active    Johnson                Jason         Professional Sales Representative
    66Active    Wainscott              Lara          Professional Sales Representative
    67Active    Aldea                  Eugen         Professional Sales Representative
    68Active    McDermott              Trinity       Professional Sales Representative
    69Active    Ford                   Abigail       Professional Sales Representative
    70Active    Embry                  Headen        Professional Sales Representative
    71Active    Psencik                Jason         Professional Sales Representative
    72Active    Cearley                Lance         Professional Sales Representative
    73Active    Lewis                  Amy           Professional Sales Representative
    74Active    Rogers                 Jennifer      Professional Sales Representative
    75Active    Schneider              Stacy         Professional Sales Representative
    76Active    Sanderson              Julie         Professional Sales Representative
    77Active    Turner                 Christy       Professional Sales Representative
    78Active    Stubblefield           Richard       Professional Sales Representative
    79Active    Black                  Michael       Professional Sales Representative
    80Active    Ray                    Lisa          Professional Sales Representative
    81Active    Herring                Jason         Professional Sales Representative
    82Active    Solomon                Wendy         Professional Sales Representative
    83Active    Daniel                 Richard       Professional Sales Representative
    84Active    Portera                Michael       Professional Sales Representative
    85Active    Ewing                  Justin        Professional Sales Representative
    86Active    Carter                 Susan         Professional Sales Representative
    87Active    Thomas                 Shane         Professional Sales Representative
    88Active    Underwood              John          Professional Sales Representative
    89Active    Murray                 Howard        Professional Sales Representative
    90Active    Mack                   Amanda        Professional Sales Representative
    91Active    Short                  Stephen       Professional Sales Representative
    92Active    Kowalski               Julie         Professional Sales Representative
    93Active    Coalson                Bryana        Professional Sales Representative
    94Active    Frick                  Betsi         Professional Sales Representative
    95Active    Mccloud                Kristina      Professional Sales Representative
    96Active    Gaulin                 John          Professional Sales Representative
    97Active    Biggings               Karen         Professional Sales Representative
    98Active    Storr                  Donnie        Professional Sales Representative
    99Active    Dahnke                 Kara          Professional Sales Representative
   100Active    Klein                  Gregory       Professional Sales Representative
   101Active    Mees                   Garry         Professional Sales Representative
   102Active    Newman                 Howard        Professional Sales Representative
   103Active    Sutherland             Catherine     Professional Sales Representative
   104Active    Ernst                  Gregory       Professional Sales Representative
   105Active    Gumbert                Joshua        Professional Sales Representative
   106Active    Berry                  Scott         Professional Sales Representative
   107Active    Routt                  Tabb          Professional Sales Representative
   108Active    Berry                  Allison       Professional Sales Representative
   109Active    Fiacable               Stephen       Professional Sales Representative
   110Active    Alex                   James         Professional Sales Representative
   111Active    Armie                  Jeff          Professional Sales Representative
   112Active    Eash                   Christopher   Professional Sales Representative
   113Active    Easter                 Kelly         Professional Sales Representative
   114Active    Polglaze               John          Professional Sales Representative
   115Active    Provan                 Joshua        Professional Sales Representative
   116Active    Methuselah             Amy           Professional Sales Representative
   117Active    Schultz                Gregory       Professional Sales Representative
   118Active    Whelton                Mary          Professional Sales Representative
   119Active    Provan                 Jacob         Professional Sales Representative
   120Active    Wright                 Melissa       Professional Sales Representative
   121Active    Bushman                Thomas        Professional Sales Representative
   122Active    Flentge                Brenda        Professional Sales Representative
   123Active    Pearson                Troy          Professional Sales Representative
   124Active    Small                  Lance         Professional Sales Representative
   125Active    Titze                  Dianne        Professional Sales Representative
   126Active    Reeg                   Debra         Professional Sales Representative
   127Active    Wayne                  Mario         Professional Sales Representative
   128Active    Knauss                 Sherri        Professional Sales Representative
   129Active    Blocker                Carlos        Professional Sales Representative
   130Active    Quinn                  Katharine     Professional Sales Representative
   131Active    Garton                 Carol         Professional Sales Representative
   132Active    Howard                 Shelly        Professional Sales Representative
   133Active    Lubin                  John          Professional Sales Representative
   134Active    Myers                  Jennifer      Professional Sales Representative
   135Active    Harris                 Michelle      Professional Sales Representative
   136Active    Parson                 Bradley       Professional Sales Representative
   137Active    McGregor               Paul          Professional Sales Representative
   138STD       (2) Harrison           Michelle      Professional Sales Representative
   139Active    Chavez                 Elle          Professional Sales Representative
   140Active    Brown                  Suzanne       Professional Sales Representative
   141Active    Zimmerman              Daniel        Professional Sales Representative
   142Active    Miller                 Megan         Professional Sales Representative
   143Active    Wood                   Brian         Professional Sales Representative
   144Active    Clark                  Cindy         Professional Sales Representative
   145Active    Peoples                Dayna         Professional Sales Representative
   146Active    Berryhill              Eric          Professional Sales Representative
   147Active    Kroll                  Charlotte     Professional Sales Representative
   148Active    Boyd-Chapman           Nancy         Professional Sales Representative
   149Active    Serwan                 Susan         Professional Sales Representative
   150Active    Harris                 Deveren       Professional Sales Representative
   151Active    Brown                  Todd          Professional Sales Representative
   152Active    Scott                  Jennifer      Professional Sales Representative
   153Active    Klaff                  Kristina      Professional Sales Representative
   154Active    Romett                 Danielle      Professional Sales Representative
   155Active    Mcanally               Judy          Professional Sales Representative
   156Active    Black                  Brittany      Professional Sales Representative
   157Active    Rodriguez              Valerie       Professional Sales Representative
   158Active    Zuliani                Chad          Professional Sales Representative
   159Active    Pribble                J.            Professional Sales Representative
   160Active    Bourguignon            Michael       Professional Sales Representative
   161Active    Current                Karen         Professional Sales Representative
   162Active    Norris                 Gary          Professional Sales Representative
   163Active    Martina                Cherie        Professional Sales Representative
   164Active    Montague               Marybeth      Professional Sales Representative
   165Active    Hopwood                Lisa          Professional Sales Representative
   166Active    Hazzard                Heidi         Professional Sales Representative
   167Active    Caine                  Colleen       Professional Sales Representative
   168Active    Moxley                 Tanya         Professional Sales Representative
   169Active    Smith                  Garrett       Professional Sales Representative
   170Active    McKnight               Ali           Professional Sales Representative
   171Active    Bershin                Kimberly      Professional Sales Representative
   172Active    Field                  Amy           Professional Sales Representative
   173Active    Dang                   Chi           Professional Sales Representative
   174Active    Kuehner                Jaime         Professional Sales Representative
   175Active    Bradley                Michael       Professional Sales Representative
   176Active    Izumi                  Bob           Professional Sales Representative
   177Active    Miller                 Tricia        Professional Sales Representative
   178Active    Raymundo               A.J           Professional Sales Representative
   179Active    Augustine              Todd          Professional Sales Representative
   180Active    Puma                   Julio         Professional Sales Representative
   181Active    Moffitt                Michael       Professional Sales Representative
   182Active    Reeves                 Elizabeth     Professional Sales Representative
   183Active    Jackson                John          Professional Sales Representative
   184Active    Reel                   Erik          Professional Sales Representative
   185Active    Palazzolo              Anthony       Professional Sales Representative
   186Active    Dixon                  Kevin         Professional Sales Representative

AREA BUSINESS MANAGERS:
-----------------------

   187Active    Gammino                Michael       Area Business Manager
   188Active    Jurney                 Scott         Area Business Manager
   189Active    Bower                  Paul          Area Business Manager
   190Active    Volpe                  Kerri         Area Business Manager
   191Active    McCormick              Audra         Area Business Manager
   192Active    Tupper                 Betsy         Area Business Manager
   193Active    Nissen                 Laura         Area Business Manager
   194Active    Rackas                 John          Area Business Manager
   195Active    Freeborn               George        Area Business Manager
   196Active    Cesarini               Louis         Area Business Manager

MEDICAL SCIENCE LIASONS:
------------------------

   197Active    Sieradzan              Ray           Medical Science Liason
   198Active    Mendez-Vigo            Luke          Medical Science Liason
   199Active    O'Donovan              Carmen        Medical Science Liason
   200Active    Ulmer                  Jack          Medical Science Liason
   201Active    Matsch                 Gregg         Medical Science Liason
   202Active    Meister                Fred          Medical Science Liason
   203Active    Lamp                   Ken           Medical Science Liason
   204Active    (3) Wisneski           Scott         Medical Science Liason
</TABLE>

   (1) Out on Short-term Disability as of June 26
   (2) Out on Short-term Disability as of July 25

                              Schedule 2(a)((beta))
                        Aventis Pre-Employment Conditions

1.       Completion of I-9 form.
2.       Completion of W-4 form.
3.       Acknowledgement of Aventis Business Conduct Policy.
4.       Disclosure of conflicts of interest.
5.       Signing of Confidentiality Agreement.
6.       Completion of payroll authorization form.
7.       Completion of personal photograph permission slip.
8.       Completion of prior employment certificate form.
9.       Receipt and acknowledgement of specific Aventis policies.
10.      Completion of certificate of employability.
11.      Completion of standard employment application form.

<PAGE>

                              Schedule 2(a)((chi))

1.       Name.
2.       Social Security Number.
3.       Home Address (Shipping address if different).
4.       Home phone.
5.       Date of birth.
6.       Country of citizenship.
7.       Gender.
8.       Marital status. Emergency Contact - Name, gender, relationship, home
         phone, office phone, cell phone.
9.       Ethnic origin - African American, Asian or Pacific Islander, Caucasian,
         Hispanic, Native American / Alaskan.
10.      Veteran status - Special disabled veteran, Vietnam-era veteran, Other
         veteran, non-veteran.
11.      Date of hire at ViroPharma or VCO (or other appropriate date on file to
         use for credited service calculation).
12.      Base salary.
13.      Existing job title.
14.      Existing grade.

<PAGE>
              Schedule 5 (a)

                       Aventis' Transition Assistance Plan

Effective for Aventis Pharmaceuticals, Inc. associates as of March 1, 2002 until
superceded

ELIGIBILITY:

Regular full time and part time associates of Aventis Pharmaceuticals Inc.
(Aventis) whose home country is the United States (excluding Puerto Rico).
Temporary or other non-regular associates (e.g., peak time, flow, prime time,
floating cadre, interns) do not participate in the Transition Assistance
Program.

Eligible associates are regular full-time and part-time active associates who
will be terminated for performance reasons, as determined by Aventis, because:

     .    Aventis has decided to terminate their employment for performance
          reasons because of their performance against the expectations set
          forth in a Written Warning and a Final Written Warning (as outlined in
          the Aventis Performance Improvement Policy); or

     .    at some point while under a Written Warning or a Final Written Warning
          for performance reasons, as determined by Aventis, under the formal
          performance improvement process (as outlined in the Aventis
          Performance Improvement Policy) they have informed their manager or
          Human Resources, in writing, that they wish to participate in this
          Transition Assistance Program.

Only associates whose termination is for performance reasons, as determined by
Aventis, are eligible for the Transition Assistance Program. Associates whose
employment ends for reasons that make them eligible for benefits under the
Separation Plan of Aventis are not eligible for the Transition Assistance
Program. Associates whose employment ends for any other reason (for example,
because of voluntary resignation, retirement, death, expiration of a leave of
absence, inability to perform for medical reasons, misconduct, insubordination,
dishonesty, breach of trust, deliberate acts contrary to the interests of
Aventis, excessive lateness or absenteeism, disclosure of confidential or
propriety information, violation of Aventis policies, or any other reason that
Aventis determines is not a performance reason for purposes of the Transition
Assistance Program), are not eligible for the Transition Assistance Program.

Note: In order to receive payments or other benefits under the Transition
Assistance Program described below, eligible associates must sign an Aventis
provided Separation Agreement and Release, and not revoke that Separation
Agreement and Release.

TRANSITION ASSISTANCE:

Transition Assistance Pay will be equal to one and one-half weeks of base pay
for each year of service. Minimum payment is two months of base pay; maximum is
nine months of base pay.

<PAGE>

Minimum amount of Transition Assistance Pay for any eligible participant is:
Grade level 60 and above:                   6 months
Grade level 50 - 55:                        4.5 months
Grade level 45:                             3 months
Grade level 40 and below:                   2 months

Transition Assistance Pay will be paid as a lump sum as soon as practicable
after your signed Separation Agreement and Release is received by Aventis (but
no earlier than 8 days after the date you sign the Separation Agreement and
Release.) Payment of the lump sum will not be made until all outstanding
balances (e.g. American Express/AT&T) are paid, and all Aventis property has
been returned to Aventis.

HEALTH CARE AND DENTAL COVERAGE:
Access to health care and dental coverage will be available at active associate
rates for a period of time coincident with the Transition Assistance period.
COBRA coverage (generally 18 months less Transition Assistance period) will be
available at the end of this time.

TRANSITION ARRANGEMENTS:

     .    Professional outplacement services will be made available.

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00041-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00041-of-00352.parquet"}]]